Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Urinary Incontinence - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Urinary Incontinence - Pipeline Review, H1 2016', provides an overview of the Urinary Incontinence pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence - The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects - The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Urinary Incontinence Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Urinary Incontinence Overview 8 Therapeutics Development 9 Pipeline Products for Urinary Incontinence - Overview 9 Pipeline Products for Urinary Incontinence - Comparative Analysis 10 Urinary Incontinence - Therapeutics under Development by Companies 11 Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes 12 Urinary Incontinence - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Urinary Incontinence - Products under Development by Companies 16 Urinary Incontinence - Products under Investigation by Universities/Institutes 17 Urinary Incontinence - Companies Involved in Therapeutics Development 18 Astellas Pharma Inc. 18 Celogos 19 Cook MyoSite Incorporated 20 Evotec AG 21 FemmePharma Global Healthcare, Inc. 22 GTx, Inc. 23 Innovacell Biotechnologie AG 24 Taiho Pharmaceutical Co., Ltd. 25 TheraVida, Inc. 26 Urinary Incontinence - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 (mirabegron + solifenacin succinate) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ASP-2205 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Cell Therapy for Urinary Incontinence - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 enobosarm - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ICES-13 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 oxybutynin hydrochloride - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Prof-003 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 RCD-1 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 TAS-303 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 THVD-201 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 THVD-202 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Urinary Incontinence - Recent Pipeline Updates 53 Urinary Incontinence - Dormant Projects 61 Urinary Incontinence - Discontinued Products 64 Urinary Incontinence - Product Development Milestones 65 Featured News & Press Releases 65 Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence 65 Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence 65 May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 66 Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 67 Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence 67 Mar 15, 2012: Innovacell to Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference 68 Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result in Study of Overactive Bladder in Vulnerable Elderly Patients 68 Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency 69 Aug 30, 2011: Innovacell passes a further milestone 69 May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 70 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development for Urinary Incontinence, H1 2016 9 Number of Products under Development for Urinary Incontinence - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Urinary Incontinence - Pipeline by Astellas Pharma Inc., H1 2016 18 Urinary Incontinence - Pipeline by Celogos, H1 2016 19 Urinary Incontinence - Pipeline by Cook MyoSite Incorporated, H1 2016 20 Urinary Incontinence - Pipeline by Evotec AG, H1 2016 21 Urinary Incontinence - Pipeline by FemmePharma Global Healthcare, Inc., H1 2016 22 Urinary Incontinence - Pipeline by GTx, Inc., H1 2016 23 Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2016 24 Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 25 Urinary Incontinence - Pipeline by TheraVida, Inc., H1 2016 26 Assessment by Monotherapy Products, H1 2016 27 Assessment by Combination Products, H1 2016 28 Number of Products by Stage and Target, H1 2016 30 Number of Products by Stage and Mechanism of Action, H1 2016 32 Number of Products by Stage and Route of Administration, H1 2016 34 Number of Products by Stage and Molecule Type, H1 2016 36 Urinary Incontinence Therapeutics - Recent Pipeline Updates, H1 2016 53 Urinary Incontinence - Dormant Projects, H1 2016 61 Urinary Incontinence - Dormant Projects (Contd..1), H1 2016 62 Urinary Incontinence - Dormant Projects (Contd..2), H1 2016 63 Urinary Incontinence - Discontinued Products, H1 2016 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.